Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Alexeev

Pain Medicine Toms River, NJ Medical Doctor

NPI 1588911226 CMS profile 4224261

1750 Route 37 W, Toms River, NJ 08757

Open in the dashboard

General payments

$3,252

60 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Alexeev of Toms River, NJ is reported in the CMS Open Payments database as having received $3,252 across 60 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $46 2
2024 General $797 6
2023 General $16 1
2022 General $271 4
2021 General $883 17
2020 General $243 12
2019 General $996 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Alexeev
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Edward Alexeev were reported at $46. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Edward Alexeev Pain Medicine median Middle half National median
2019 $996 $409 $115–$1,311 $163
2020 $243 $214 $66–$666 $114
2021 $883 $299 $84–$899 $132
2022 $271 $335 $103–$1,149 $149
2023 $16 $376 $114–$1,228 $160
2024 $797 $387 $115–$1,173 $164
2025 $46 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,158 43 payments
  2. Medtronic, Inc. $543 3 payments
  3. Medtronic USA, Inc. $241 3 payments
  4. Alphatec Spine, Inc $143 1 payment
  5. Abbott Laboratories $142 9 payments
  6. BIOTRONIK NRO, Inc. $24 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,044 59 payments
  2. Grant $208 1 payment
Products named General payments · program years 2019–2025
  1. GENERAL PAIN MANAGEMENT $915 19 payments
  2. INTELLIS ADAPTIVESTIM $543 3 payments
  3. WAVEWRITER ALPHA $228 3 payments
  4. SYNCHROMED $208 1 payment
  5. GENERAL - PAIN MANAGEMENT Pain Management $192 8 payments
  6. General - Pain Management General - Pain Management_NMD $177 4 payments
  7. Invictus MIS $143 1 payment
  8. WaveWriter Alpha Prime 16 $139 2 payments
  9. SPECTRA WAVEWRITER Pain Management $113 1 payment
  10. SPECTRA WAVEWRITER Pain Management $110 1 payment
  11. Other $398 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

265

Median for Interventional Pain Management: 1,220

Drug cost

$3,543

Median for Interventional Pain Management: $39,344

Branded share of claims

21.9%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 42 $1,827
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 32 $469
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 26 $378
Oxycodone Hcl Generic 34 $190
Tramadol Hcl Generic 38 $158
Meloxicam Generic 28 $127
Methylprednisolone Generic 15 $123
Pregabalin Generic 19 $105
Gabapentin Generic 15 $88
Cyclobenzaprine Hcl Generic 16 $79

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$354,749

Of which drugs: $8,339

Medicare patients

610

Average age 79

Services billed

6,796

365 women, 245 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 69%
Diabetes 60%
Ischemic heart disease 55%
Depression 52%
Heart failure 45%
Chronic kidney disease 43%
COPD 40%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 113 852 $646

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record